NCT00458978 - Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2014

Conditions

Recurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Laryngeal Verrucous CarcinomaRecurrent Lip and Oral Cavity Squamous Cell CarcinomaRecurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult PrimaryRecurrent Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaRecurrent Nasopharyngeal Keratinizing Squamous Cell CarcinomaRecurrent Oral Cavity Verrucous CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Salivary Gland CarcinomaSalivary Gland Squamous Cell CarcinomaSquamous Cell Carcinoma Metastatic in the Neck With Occult PrimaryStage IV Hypopharyngeal Squamous Cell CarcinomaStage IV Laryngeal Squamous Cell CarcinomaStage IV Laryngeal Verrucous CarcinomaStage IV Lip and Oral Cavity Squamous Cell CarcinomaStage IV Major Salivary Gland CarcinomaStage IV Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IV Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IV Oral Cavity Verrucous CarcinomaStage IV Oropharyngeal Squamous Cell CarcinomaTongue CarcinomaUntreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary

Interventions

DRUG

Cediranib Maleate

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH